Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?
Christoph WetzJulian RogaschPhilipp GensekeImke SchatkaChristian FurthMichael Christoph KreisslHenning JannMarino VeneritoHolger AmthauerPublished in: Diagnostics (Basel, Switzerland) (2020)
pretherapeutic ASP of SSR positive lesions independently predicted PFS for treatment with everolimus in GEP-NET. ASP may supplement risk-benefit assessment before patient inclusion to treatment.